financetom
Business
financetom
/
Business
/
Musk's X accuses advertisers of illegal boycott in new lawsuit
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Musk's X accuses advertisers of illegal boycott in new lawsuit
Aug 6, 2024 9:53 AM

Aug 6 (Reuters) - Elon Musk's social media platform X on

Tuesday sued a global advertising alliance and several major

companies, including Mars and CVS Health ( CVS ), accusing them of

unlawfully conspiring to boycott the site and causing it to lose

revenue.

X filed the lawsuit in federal court in Texas against the

World Federation of Advertisers, Unilever ( UL ) and Danish

renewable energy company Orsted, in addition to Mars and CVS

Health ( CVS ).

The lawsuit said advertisers, acting through a World

Federation of Advertisers initiative called Global Alliance for

Responsible Media, collectively withheld "billions of dollars in

advertising revenue" from X, previously known as Twitter.

It said they acted against their own economic self interests

in a conspiracy against the platform that violated U.S.

antitrust law.

The World Advertising Federation, Unilever ( UL ), Mars, CVS Health ( CVS )

and Orsted did not immediately respond to requests for comment.

In a statement on Tuesday about the lawsuit, X's chief

executive Linda Yaccarino said "people are hurt when the

marketplace of ideas is constricted. No small group of people

should monopolize what gets monetized."

Ad revenue at X slumped for months after Musk bought the

company in 2022. Brands had been wary of rapid changes initiated

under Musk's ownership.

The advertising group launched the responsible media

initiative in 2019 to "help the industry address the challenge

of illegal or harmful content on digital media platforms and its

monetization via advertising."

X said in its lawsuit that it has applied brand-safety

standards that are comparable to those of its competitors and

that "meet or exceed" measures specified by the Global Alliance

for Responsible Media.

The lawsuit said X has become a "less effective competitor"

in the sale of digital advertising.

X is seeking unspecified damages and a court order against

any continued efforts to conspire to withhold ad dollars.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Northwest Natural Holding Insider Sold Shares Worth $297,611, According to a Recent SEC Filing
Northwest Natural Holding Insider Sold Shares Worth $297,611, According to a Recent SEC Filing
Jun 24, 2025
04:52 PM EDT, 06/24/2025 (MT Newswires) -- David Hugo Anderson, Director, on June 20, 2025, sold 7,500 shares in Northwest Natural Holding ( NWN ) for $297,611. Following the Form 4 filing with the SEC, Anderson has control over a total of 105,170 common shares of the company, with 94,791 shares held directly and 10,379 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1733998/000173399825000113/xslF345X05/form4.xml...
Hagerty Insider Sold Shares Worth $508,865, According to a Recent SEC Filing
Hagerty Insider Sold Shares Worth $508,865, According to a Recent SEC Filing
Jun 24, 2025
04:53 PM EDT, 06/24/2025 (MT Newswires) -- Robert I Kauffman, Director, on June 20, 2025, sold 50,567 shares in Hagerty ( HGTY ) for $508,865. Following the Form 4 filing with the SEC, Kauffman has control over a total of 3,805,806 Class A common shares of the company, with 67,302 shares held directly and 3,738,504 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1840776/000184077625000182/xslF345X05/wk-form4_1750798040.xml...
Anterix Swings to Fiscal Q4 Profit, Revenue Rises
Anterix Swings to Fiscal Q4 Profit, Revenue Rises
Jun 24, 2025
04:53 PM EDT, 06/24/2025 (MT Newswires) -- Anterix ( ATEX ) reported fiscal Q4 earnings late Tuesday of $0.49 per diluted share, compared with a loss of $0.51 a year earlier. Three analysts polled by FactSet expected a loss of $0.46. Spectrum revenue for the quarter ended March 31 was $1.4 million, up from $1.3 million a year earlier. Three...
Verastem Doses First Patient in US Study of Oral Cancer Drug VS-7375
Verastem Doses First Patient in US Study of Oral Cancer Drug VS-7375
Jun 24, 2025
04:53 PM EDT, 06/24/2025 (MT Newswires) -- Verastem ( VSTM ) said late Tuesday it has dosed the first patient in its US phase 1/2a trial of VS-7375, an investigational oral inhibitor targeting KRAS G12D mutant solid tumors. The study is designed to assess the safety and efficacy of VS-7375 and is being conducted in the US with plans for...
Copyright 2023-2025 - www.financetom.com All Rights Reserved